Lipid based particulate formulations for the delivery of antigen

Particulate adjuvant systems are largely classified according to their functional characteristics, such as the nature of the typical immune response they induce, or their perceived mode of action. From a formulation science perspective, it is practical to classify antigen delivery systems according to the physical nature of the formulations. This article discusses lipid based particulate systems, grouped according to the nature of their predominant lipid constituent.

[1]  B. Rönnberg,et al.  Isolation and quantification of Quillaja saponaria Molina saponins and lipids in iscom-matrix and iscoms. , 1995, Vaccine.

[2]  C. Alving.  Design and selection of vaccine adjuvants: animal models and human trials. , 2002, Vaccine.

[3]  S. Stacey,et al.  Priming in vivo and quantification in vitro of class I MHC-restricted cytotoxic T cells to human papilloma virus type 11 early proteins (E6 and E7) using immunostimulating complexes (ISCOMs). , 1996, Vaccine.

[4]  Rajesh K. Gupta,et al.  Adjuvants--a balance between toxicity and adjuvanticity. , 1993, Vaccine.

[5]  M. Parnham,et al.  Toxicity screening of liposomes. , 1993, Chemistry and physics of lipids.

[6]  D. Pardoll,et al.  Therapeutic potential of protein and adjuvant vaccinations on tumour growth. , 2001, Vaccine.

[7]  G. Cevc.  Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. , 1996, Critical reviews in therapeutic drug carrier systems.

[8]  C. Alving,et al.  Liposomes Containing Lipid A Serve as an Adjuvant for Induction of Antibody and Cytotoxic T-Cell Responses against RTS,S Malaria Antigen , 1998, Infection and Immunity.

[9]  G. Reid,et al.  Soluble proteins incorporate into ISCOMs after covalent attachment of fatty acid. , 1992, Vaccine.

[10]  Andreas G. Schätzlein,et al.  Ultraflexible vesicles, Transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin. , 1998, Biochimica et biophysica acta.

[11]  R. New,et al.  Liposomes : a practical approach , 1990 .

[12]  R. Bomford,et al.  Adjuvanticity and ISCOM formation by structurally diverse saponins. , 1992, Vaccine.

[13]  D. Small.  A classification of biologic lipids based upon their interaction in aqueous systems , 1968, Journal of the American Oil Chemists' Society.

[14]  H. Merkle,et al.  Hydrophilic poly(DL-lactide-co-glycolide) microspheres for the delivery of DNA to human-derived macrophages and dendritic cells. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[15]  A. Podda.  The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. , 2001, Vaccine.

[16]  P. Tyler,et al.  Liposomal delivery of antigen to human dendritic cells. , 2003, Vaccine.

[17]  R. Müller,et al.  Nanostructured lipid matrices for improved microencapsulation of drugs. , 2002, International journal of pharmaceutics.

[18]  J. Gomez-Fernandez,et al.  Stability of Liposomes on Long Term Storage , 1990, The Journal of pharmacy and pharmacology.

[19]  J. Engberts,et al.  Formation and stability of micelles and vesicles , 1996 .

[20]  R. Zinkernagel.  On cross‐priming of MHC class I‐specific CTL: rule or exception? , 2002, European journal of immunology.

[21]  J. Viret,et al.  Virosomal adjuvanted antigen delivery systems , 2003, Expert review of vaccines.

[22]  T. Allen,et al.  Uptake of liposomes by cultured mouse bone marrow macrophages: influence of liposome composition and size. , 1991, Biochimica et biophysica acta.

[23]  V. Price,et al.  2nd meeting on novel adjuvants currently in/close to human clinical testing. World Health Organization-Organization Mondiale de la Santé Fondation Mérieux, Annecy, France, 5-7 June 2000. , 2002, Vaccine.

[24]  K. Mäder,et al.  Solid lipid nanoparticles: production, characterization and applications. , 2001, Advanced drug delivery reviews.

[25]  J. Muderhwa,et al.  Oil-in-water liposomal emulsions: characterization and potential use in vaccine delivery. , 1999, Journal of pharmaceutical sciences.

[26]  Derek T. O'Hagan,et al.  Recent Advances in Vaccine Adjuvants , 2002, Pharmaceutical Research.

[27]  J. Wilschut,et al.  Virosome-mediated delivery of protein antigens to dendritic cells. , 2002, Vaccine.

[28]  J. Bates,et al.  Studies on experimental adjuvanted influenza vaccines: comparison of immune stimulating complexes (Iscoms) and oil-in-water vaccines. , 1998, Vaccine.

[29]  K. Maloy,et al.  Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens. , 1993, Immunology.

[30]  R. Gupta,et al.  Adjuvants for human vaccines--current status, problems and future prospects. , 1995, Vaccine.

[31]  M. Villacrés-Eriksson.  Antigen presentation by naive macrophages, dendritic cells and B cells to primed T lymphocytes and their cytokine production following exposure to immunostimulating complexes , 1995, Clinical and experimental immunology.

[32]  I. Barr,et al.  ISCOMs and other saponin based adjuvants. , 1998, Advanced drug delivery reviews.

[33]  S. Gohla,et al.  Production of solid lipid nanoparticles (SLN): scaling up feasibilities , 2002, Journal of microencapsulation.

[34]  A. Schätzlein,et al.  Ultradeformable lipid vesicles can penetrate the skin and other semi-permeable barriers unfragmented. Evidence from double label CLSM experiments and direct size measurements. , 2002, Biochimica et biophysica acta.

[35]  M. Kieny,et al.  4th meeting on Novel Adjuvants Currently in/close to Human Clinical Testing World Health Organization -- organisation Mondiale de la Santé Fondation Mérieux, Annecy, France, 23-25, June 2003. , 2004, Vaccine.

[36]  L. Leserman,et al.  Class I‐restricted presentation of exogenous antigen acquired by Fcγ receptor‐mediated endocytosis is regulated in dendritic cells , 2000, European journal of immunology.

[37]  J. Aucouturier,et al.  Adjuvants designed for veterinary and human vaccines. , 2001, Vaccine.

[38]  C. Alving,et al.  Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. mangala.rao@na.amedd.army.mil. , 2000, Advanced drug delivery reviews.

[39]  G. Gregoriadis.  Immunological adjuvants: a role for liposomes. , 1990, Immunology today.

[40]  R. Müller,et al.  Stable Biocompatible Adjuvants — a New Type of Adjuvant Based on Solid Lipid Nanoparticles: A Study on Cytotoxicity, Compatibility and Efficacy in Chicken , 2002, Alternatives to laboratory animals : ATLA.

[41]  Alfred N. Martin.  Physical Pharmacy: Physical Chemical Principles in the Pharmaceutical Sciences , 1969 .

[42]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[43]  Small Dm.  Surface and bulk interactions of lipids and water with a classification of biologically active lipids based on these interactions. , 1970 .

[44]  A. Osterhaus,et al.  Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses , 1984, Nature.

[45]  M. Zignani,et al.  Current status of pH-sensitive liposomes in drug delivery. , 2000, Progress in lipid research.

[46]  R. Müller,et al.  Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. , 2002, International journal of pharmaceutics.

[47]  A. Emili,et al.  Immunogenicity of immunoliposomes. , 1991, Immunology letters.

[48]  G. Riveau,et al.  Influence of phospholipid composition on antibody responses to liposome encapsulated protein and peptide antigens. , 1996, Vaccine.

[49]  R. Müller,et al.  Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[50]  F Ambrosch,et al.  Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. , 1997, Vaccine.

[51]  L. Huang,et al.  Delivery of protein antigen to the major histocompatibility complex class I-restricted antigen presentation pathway. , 1995, Journal of drug targeting.

[52]  M. Villacres,et al.  Internalization of iscom-borne antigens and presentation under MHC class I or class II restriction. , 1998, Cellular immunology.

[53]  G. Cevc,et al.  Transdermal immunisation with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transfersomes. , 1998, Vaccine.

[54]  B. Rouse,et al.  pH sensitive liposomes provide an efficient means of sensitizing target cells to class I restricted CTL recognition of a soluble protein. , 1991, Journal of immunological methods.

[55]  S Murdan,et al.  Sorbitan monostearate/polysorbate 20 organogels containing niosomes: a delivery vehicle for antigens? , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[56]  V. Schijns,et al.  Mechanisms of vaccine adjuvant activity: initiation and regulation of immune responses by vaccine adjuvants. , 2003, Vaccine.

[57]  J. Grivel,et al.  Efficient presentation of multivalent antigens targeted to various cell surface molecules of dendritic cells and surface Ig of antigen-specific B cells. , 1998, Journal of immunology.

[58]  R. Müller,et al.  Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[59]  H. Junginger,et al.  Niosomes as a novel peroral vaccine delivery system. , 1999, International journal of pharmaceutics.

[60]  N. Weiner,et al.  The influence of lipid composition and lamellarity of liposomes on the physical stability of liposomes upon storage , 1996 .

[61]  A. Suhrbier,et al.  Immune responses to ISCOM formulations in animal and primate models. , 2001, Vaccine.

[62]  A. Osterhaus,et al.  A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. , 2000, Vaccine.

[63]  D. Crommelin,et al.  Liposomes and ISCOMS as vaccine formulations. , 1995, Biochimica et biophysica acta.

[64]  Manmohan J. Singh,et al.  Advances in vaccine adjuvants , 1999, Nature Biotechnology.